Skip to main content
Clinical Trials/NCT05886127
NCT05886127RecruitingNot Applicable

Treatment of Immediate and Prevention of Delayed Bleeding After Endoscopic Retrograde Cholangiopancreatography Sphincterothomy or Precut With a Novel Self-assembling Peptide Hemostatic Gel. A Single Centre Prospective Observational Nonrandomized Study

General University Hospital, Prague1 site in 1 country80 target enrollmentStarted: August 1, 2022Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
80
Locations
1
Primary Endpoint
Number of bleeding episodes after ERCP sfincterothomy or precut

Study Overview

Brief Summary

The aim of this observational study is to evaluate safety and efficacy of a novel self-assembling peptide hemostatic gel in reduction of bleeding after endoscopic sphincterotomy during ERCP (endoscopic retrograde cholangiopancreatography )

Detailed Description

ERCP with sfincterotomy or precut is connected with procedural or/and postprocedural bleeding. Estimated risk of bleeding is from 2% to 10%. Procedural bleeding is usually managed by diluted epinephrine injection, balloon tamponade, hemoclip or fully covered metalic self-expanding stent placement. There is no standard preventive treatment for patients with higher risk of delayed post-sphincterotomy bleeding. PuraStat®, 3D Matrix Europe SAS, Caluire-et-Cuire, France) is synthetic self-assembling peptide haemostatic gel indicated to stop bleeding from small blood vessel or oozing from capillaries. Purastat® is easily aplicated through a catheter during the ERCP procedure and it is not significantly prolonging the procedure. The transparent gel is not compromising the endoscopic view and enables to continue in procedure if necessary.

All patients after ERCP sfincterotomy or precut will recieve Purastat® during the procedure Adverse events (bleeding, cholangoitis, pancreatitis) will be monitored during following 4 weeks (ambulatory after hospital discharge) This cohort will be compared to historical control, when Purastat® was not available tu use.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Other

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • . All patients indicated for ERCP with papilosphincterotomy or precut.
  • Participant is willing and able to give informed consent for participation in the study

Exclusion Criteria

  • Known allergy to a novel hemostatic agent
  • Gravidity
  • Inability to sign informed consent

Outcomes

Primary Outcomes

Number of bleeding episodes after ERCP sfincterothomy or precut

Time Frame: One month

Secondary Outcomes

  • Number of nonbleeding complications after ERCP sfincterothomy or precut(One month)

Investigators

Sponsor
General University Hospital, Prague
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Petr Hrabak

Principal investigator

General University Hospital, Prague

Study Sites (1)

Loading locations...

Similar Trials